This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Memantine effects on verbal memory in fragile X-associated tremor/ataxia syndrome (FXTAS): A double-blind brain potential study


Yang, Jin-Chen, Niu, Yu-Qiong, Simon, Christa, Seritan, Andreea L, Chen, Lawrence, Schneider, Andrea, Moghaddam, Shayan T, Hagerman, Paul J, Hagerman, Randi J, Olichney, John M


Neuropsychopharmacology, Volume: 39, No.: 12, Pages.: 2760-2768

Year of Publication



Older FMR1 premutation carriers may develop fragile X-associated tremor/ataxia syndrome (FXTAS), a neurodegenerative disorder manifesting cognitive deficits that often subsequently progress to dementia. To date, there is no specific treatment available for FXTAS. Studies have demonstrated the premutation-associated overactivation of glutamatergic receptors in neurons. Memantine, a NMDA receptor antagonist approved for treatment of Alzheimer’s disease, thus was tested in the first placebo-controlled, double-blind, randomized clinical trial in FXTAS. Prior event-related brain potential (ERP) studies in FXTAS found reduced N400 repetition effect, a glutamate-related electrophysiological marker of semantic priming, and verbal memory processes. This substudy of the randomized clinical trial of memantine in FXTAS sought to use the N400 repetition effect to evaluate effects of chronic memantine treatment on verbal memory. Subsequent recall and recognition memory tests for the experimental stimuli were administered to characterize verbal memory. Data from 41 patients who completed the 1-year memantine trial (21 on memantine) and also completed longitudinal ERP studies were analyzed. Results showed treatment-associated benefits on both cued-recall memory and N400 repetition effect amplitude. Importantly, improvement in cued recall was positively correlated with amplitude increase of the N400 repetition effect. The placebo group, in contrast, displayed a significant reduction of the N400 repetition effect after 1 year. These results suggest that memantine treatment may have beneficial effects on verbal memory in FXTAS. Additional studies of memantine, perhaps in combination with other therapeutic agents, appear warranted, as symptomatic treatments and neuroprotective treatments are both needed for this recently recognized neurodegenerative disorder. (PsycINFO Database Record (c) 2015 APA, all rights reserved). (journal abstract)

Bibtex Citation

@article{Yang_2014, doi = {10.1038/npp.2014.122}, url = {}, year = 2014, month = {may}, publisher = {Nature Publishing Group}, volume = {39}, number = {12}, pages = {2760--2768}, author = {Jin-Chen Yang and Yu-Qiong Niu and Christa Simon and Andreea L Seritan and Lawrence Chen and Andrea Schneider and Shayan T Moghaddam and Paul J Hagerman and Randi J Hagerman and John M Olichney}, title = {Memantine Effects on Verbal Memory in Fragile X-associated Tremor/Ataxia Syndrome ({FXTAS}): a Double-Blind Brain Potential Study}, journal = {Neuropsychopharmacology} }


ataxia, ataxia syndrome, drug therapy, fragile, fragile x syndrome, fragile xassociated tremor, memantine effects, nmethyldaspartate receptor, people, syndrome, tremor, verbal memory, with, x

Countries of Study


Types of Study

Before and After Study

Type of Outcomes


Type of Interventions

Risk Factor Modification

Risk Factor Modifications

At risk population